The American regulator's warning about the possible risk of vision loss when taking GLP-1 drugs, including Ozempi, requires consideration by doctors and patients, but in itself does not mean the need to refuse the prescribed treatment. Egor Kostyukov, an ophthalmologist and eye surgeon of the highest category at the VISTA clinic, told RBC about it.
According to Kostyukov, the first signs of a possible connection concerned semaglutide, the active ingredient in Ozmpic. He considers the FDA's decision to extend the warning to the entire GLP-1 class justified.
"At the same time, it is important to correctly assess the scale. The absolute risk is very low, even according to conservative estimates, it is no more than an additional case per 10,000 patients per year. Therefore, in my opinion, this is not a reason to refuse the treatment prescribed according to the labels," said the doctor.